Merck news

Enlicitide shows significant LDL-C reduction and favorable safety in Phase 3 trials, meeting all primary and key secondary endpoints for hypercholesterolemia treatment.

Vericiguat didn't reduce primary endpoint risk in HFrEF patients but showed fewer cardiovascular deaths. Safety profile consistent with previous trials.

The acquisition involves a €500M investment, adding 1,000 jobs across Ireland by 2025, enhancing vaccine production capabilities and strengthening Ireland's pharma sector.

The new 10,000 sqm facility in Darmstadt will house 135 employees, meet sustainability standards, and enhance quality control for life science products, supporting Merck's €1.5B investment program.

The new center will focus on antibody and mRNA research, supporting 550 employees by 2027. It aims for near carbon-neutral operations and gold certification from the German Sustainable Building Council.

The investment will boost single-use assembly production, create 800 jobs by 2028, and support growth in novel therapies and vaccines, aligning with sustainability goals and global expansion plans.

Over 100 new jobs will be created as a new facility for next-gen oncology biologics begins construction, operational by 2025, adding to the existing 530 staff and 700 construction roles.

The investment will boost membrane and filtration manufacturing, create 370 jobs by 2027, and support novel therapies, vaccines, and diagnostics, aligning with sustainability goals.

€150M investment in Aubonne, Switzerland, for new building with advanced tech to boost production of biotech medicines, meeting global demand. Completion expected by 2023.

The investment will enhance RTU Media production, ensure supply security, and centralize R&D in Molsheim, supporting global demand and market growth.

The investment will expand production for rising biopharmaceutical demand, focusing on sterile filling and packaging. The Bari site benefits from skilled employees and good infrastructure.